Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 17Leukemia 12Breast Neoplasms 12Prostatic Neoplasms 10Neoplasm Metastasis 8Recurrence 6Pancreatic Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Melanoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Philadelphia Chromosome 4Multiple Myeloma 4Lymphoma 4Burkitt Lymphoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Ovarian Neoplasms 3Glioma 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Neuroblastoma 2Leukemia, Myelomonocytic, Chronic 2

Interventions

midostaurin 3avapritinib 2sarilumab 1obatoclax 1ibrutinib 1denileukin diftitox 1Imatinib Mesylate 1Everolimus 1Dasatinib 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mastocytosis, Systemic × Dasatinib × Clear all
NCT00979160 2009-09-18

Evaluation of Response of Dasatinib to Treat Mastocytosis

Federico II University

Phase 2 Unknown
30 enrolled
Myeloid

Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡